We are dedicated to providing resources to patients, practicing clinicians, and all individuals concerned w/ improving the care of patients with kidney disease.
Insight of the Week - Kidney care is evolving—new IgA nephropathy targets, advanced diagnostics like mNGS, and precision medicine are driving earlier detection & tailored treatments for better outcomes. Support research & advocate for kidney health. #Nephrology#Innovation
CHANCE-2 trial: In stroke pts w/ CYP2C19 LOF, ticagrelor cut stroke risk in both age groups w/ normal kidneys, but no benefit in mild impairment. #Stroke#Nephrology
https://t.co/BxZPKhgtC4
Multi-institutional study in pediatric lupus shows reliable capture of BP, proteinuria & RAAS inhibitor use across 6 sites. Findings reveal high hypertension/proteinuria rates, variation in treatment, & opportunities to standardize care. #PediatricLupus https://t.co/3PVdCiLIWW
💊 Breakthrough in Lupus Nephritis Treatment!
Results from the REGENCY phase 3 trial show that adding obinutuzumab to standard therapy significantly improved kidney outcomes in adults with active lupus nephritis. https://t.co/t5TTU3RyHD
A dual GLP-1 & glucagon receptor agonist, significantly reduced urinary albumin-to-creatinine ratio (UACR) in patients w/ type 2 diabetes & chronic kidney disease. At 14 weeks, reductions reached ~44% w/ 300 μg & ~50% with 600 μg versus placebo, w/ effects sustained at 26 weeks.
🌟 Nephrology is evolving—precision medicine, advanced therapies, AI, next-gen diagnostics & whole-patient wellness are transforming kidney care. The goal: longer, healthier lives & smarter decisions for patients. #Nephrology#KidneyHealth#Innovation#PatientCare
🧪 Promising Results in IgA Nephropathy!
A phase 3 trial shows that atrasentan, a selective endothelin A receptor antagonist, significantly reduced proteinuria in patients with IgA nephropathy and high kidney risk.
#KidneyResearch 🔗 Learn more: https://t.co/BY6eGLu31t
Breakthrough in Lupus Nephritis Treatment! Results from the REGENCY phase 3 trial show that adding obinutuzumab to standard therapy significantly improved kidney outcomes in adults with active lupus nephritis. Read more: https://t.co/pu9IKk1ySl
#LupusNephritis#ClinicalTrials
Phase 3 APPEAR-C3G trial:
Iptacopan (LNP023) cut proteinuria by 35% vs placebo at 6 months in C3 glomerulopathy.
Well-tolerated with no meningococcal infections or treatment discontinuations.
#nephrology.
#C3G#ClinicalTrials#KidneyResearch
https://t.co/o1hDEsXpwt
🧪 Post hoc AURORA 1 analysis: voclosporin did not alter kidney injury or pro-fibrotic biomarkers (KIM-1, TGF-β1, MCP-1, NGAL) vs MMF + steroids in lupus nephritis—supporting renal safety.
🔗 https://t.co/SLgK2MTclQ
#LupusNephritis#Nephrology#Voclosporin#KidneyBiomarkers